

From: thorbjorg.kjartansdottir@lyfjastofnun.is
Sent: 08 April 2008 12:57
To: NARHI Ulla (ENTR)
Cc: rannveig.gunnarsdottir@lyfjastofnun.is
Subject: LEGAL PROPOSAL ON INFORMATION TO PATIENTS - Public Consultation

Dear Mrs Ulla Nähri,

Regarding Public Consultation on LEGAL PROPOSAL ON INFORMATION TO PATIENTS the Icelandic Medicines Control Agency (IMCA) would like to point out the following:

- The work of the Pharmaceutical Forum, Information to Patients Working Group is to be recommended, where discussion focuses on Public Private Partnership and information is validated before it is published.
- We can not see any added value for patients in "stand alone" information from the Pharmaceutical industry.
- We expect much additional workload in supervising information from the industry, without seeing any benefit for the patients.

On behalf of Mrs. Rannveig Gunnarsdottir Executive Director of IMCA

Thorbjorg Kjartansdottir

LYFJASTOFNUN
ICELANDIC MEDICINES CONTROL AGENCY
Þorbjörg Kjartansdóttir, lyfjafræðingur/Pharmacist
Sviðsstjóri skráningarsviðs/Head of Licencing Unit
Eiðistorg 13-15, 170 Seltjarnarnes, Iceland
Sími/Tel.: + 354 520 2100, Símbréf/Fax: + 354 561 2170
Netfang/e-mail - thorbjorg.kjartansdottir@lyfjastofnun.is
Veffang/website - www.lyfjastofnun.is

Vinsamlegast athugið að upplýsingar í tölvupósti þessum og viðhengjum hans eru eingöngu ætlaðar þeim sem póstinum er beint til og gætu innihaldið upplýsingar sem eru trúnaðarmál.

Please note that this e-mail and attachments are intended for the named addressee only and may contain information that is confidential and privileged.